Evidence map›Paper›PMID 29614121›Full record

ArticlePloS one2018

Dominant serotype distribution and antimicrobial resistance profile of Shigella spp. in Xinjiang, China.

Hongbo Liu, Binghua Zhu, Shaofu Qiu, Yidan Xia, Beibei Liang, Chaojie Yang, Nian Dong, Yongrui Li, Ying Xiang, Shan Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Human vaccines & immunotherapeutics · 2026
    Review
  2. Article
  3. Article
  4. Healthcare (Basel, Switzerland) · 2025
    Article
  5. AnalyzingInfection and drug resistance · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Burden, Antibiotic Resistance, and Clonality ofTropical medicine and infectious disease · 2021
    Article
  12. High Resistance ofTropical medicine and infectious disease · 2021
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Hongbo LiuAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Binghua ZhuAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Shaofu QiuInstitute of Disease Control and Prevention, PLA, Beijing, China.
Yidan XiaCenter for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, Urumqi, China.
Beibei LiangAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Chaojie YangInstitute of Disease Control and Prevention, PLA, Beijing, China.
Nian DongAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Yongrui LiInstitute of Disease Control and Prevention, PLA, Beijing, China.
Ying XiangAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Shan WangAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Jing XieInstitute of Disease Control and Prevention, PLA, Beijing, China.
Muti MaheCenter for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, Urumqi, China.
Yansong SunAcademy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.
Hongbin SongInstitute of Disease Control and Prevention, PLA, Beijing, China.ORCID 0000-0002-2781-3031
Academy of Military Medical Sciences · CNBeijing Center for Disease Prevention and Control · CNXinjiang Uygur Autonomous Region Disease Prevention and Control Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shigella represents one of the major diarrhea-inducing pathogens threatening public health, but its prevalence and antimicrobial resistance profile in Xinjiang Uygur Autonomous region, China, remains unclear. We conducted comprehensive investigation of Shigella serotype distribution and antimicrobial resistance pattern in Xinjiang, identifying 458 Shigella isolates between 2008 to 2014. Shigella flexneri was identified as predominant species, and several S. flexneri serotypes were isolated, including atypical serotypes 1c, 2c, and 4s. Dominant S. flexneri serotypes were 2a, 1b, 2b, and Xv, different from those generally dominant in China. A hybrid serotype pattern was observed, which included the major Chinese serotypes (2a, Xv) and those predominant in Pakistan (1b, 2b). Shigella sonnei was shown to have a lower frequency compared with that generally observed in China, but an increasing trend of infections associated with this pathogen was observed. Furthermore, a high frequency of drug resistance and different Shigella antimicrobial resistance patterns were demonstrated as well, including very severe resistance phenotypes, such as multidrug resistance and resistance to frontline antibiotics. Seventy-five cephalosporin-resistant Shigella isolates were frequently identified with the resistance determinants that can undergo horizontal transfer, such as blaOXA, blaTEM, blaCTX-M, and integrons, facilitating the development of cephalosporin resistance among Shigella subtypes. Additionally, genetic analyses demonstrated that all 86 quinolone-resistant S. flexneri isolates possess 3-4 mutation sites in quinolone resistance-determining regions, primarily contributing to their resistance to quinolone. However, S. sonnei isolates were not shown to be quinolone resistant. Co-resistance to cephalosporins and quinolones was detected in 17 S. flexneri isolates, and these isolates were additionally multidrug resistant and carried β-lactamase genes and quinolone-resistance determinants. As is demonstrated in this study, dominant serotypes of Shigella were distributed in unique trend with dangerous drug resistance patterns. Novel strategies are urgently required to prevent the development of drug resistance among diarrhea-inducing pathogens.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsChinaDNA, BacterialDysentery, BacillaryFecesFemaleHumansMaleSerogroupShigellaTime FactorsAnti-Bacterial AgentsDNA, Bacterial

Identifiers

PMID29614121
PMCPMC5882154
OpenAlexW2795838041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.